175 related articles for article (PubMed ID: 25558221)
1. Baicalin and deferoxamine alleviate iron accumulation in different brain regions of Parkinson's disease rats.
Xiong P; Chen X; Guo C; Zhang N; Ma B
Neural Regen Res; 2012 Sep; 7(27):2092-8. PubMed ID: 25558221
[TBL] [Abstract][Full Text] [Related]
2. Baicalin suppresses iron accumulation after substantia nigra injury: relationship between iron concentration and transferrin expression.
Guo C; Chen X; Xiong P
Neural Regen Res; 2014 Mar; 9(6):630-6. PubMed ID: 25206866
[TBL] [Abstract][Full Text] [Related]
3. Detecting dopaminergic neuronal degeneration using diffusion tensor imaging in a rotenone-induced rat model of Parkinson's disease: fractional anisotropy and mean diffusivity values.
Liu LX; Du D; Zheng T; Fang Y; Chen YS; Yi HL; He QY; Gao DW; Shi QL
Neural Regen Res; 2017 Sep; 12(9):1485-1491. PubMed ID: 29089995
[TBL] [Abstract][Full Text] [Related]
4. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
[TBL] [Abstract][Full Text] [Related]
5. Intrapallidal lipopolysaccharide injection increases iron and ferritin levels in glia of the rat substantia nigra and induces locomotor deficits.
Zhang J; Stanton DM; Nguyen XV; Liu M; Zhang Z; Gash D; Bing G
Neuroscience; 2005; 135(3):829-38. PubMed ID: 16165292
[TBL] [Abstract][Full Text] [Related]
6. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Youdim MB; Stephenson G; Ben Shachar D
Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
[TBL] [Abstract][Full Text] [Related]
7. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
8. Brain iron accumulation exacerbates the pathogenesis of MPTP-induced Parkinson's disease.
You LH; Li F; Wang L; Zhao SE; Wang SM; Zhang LL; Zhang LH; Duan XL; Yu P; Chang YZ
Neuroscience; 2015 Jan; 284():234-246. PubMed ID: 25301748
[TBL] [Abstract][Full Text] [Related]
9. Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson's disease.
Carriere CH; Kang NH; Niles LP
Brain Res; 2016 Feb; 1633():115-125. PubMed ID: 26740407
[TBL] [Abstract][Full Text] [Related]
10. Time-dependent changes in iron levels and associated neuronal loss within the substantia nigra following lesions within the neostriatum/globus pallidus complex.
Sastry S; Arendash GW
Neuroscience; 1995 Aug; 67(3):649-66. PubMed ID: 7545796
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease.
Carriere CH; Kang NH; Niles LP
Neuroscience; 2014 May; 267():114-21. PubMed ID: 24613722
[TBL] [Abstract][Full Text] [Related]
12. Ginsenoside Rb1 protects dopaminergic neurons from inflammatory injury induced by intranigral lipopolysaccharide injection.
Li DW; Zhou FZ; Sun XC; Li SC; Yang JB; Sun HH; Wang AH
Neural Regen Res; 2019 Oct; 14(10):1814-1822. PubMed ID: 31169200
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effects of iron chelator Desferal on dopaminergic neurons in the substantia nigra of rats with iron-overload.
Jiang H; Luan Z; Wang J; Xie J
Neurochem Int; 2006 Nov; 49(6):605-9. PubMed ID: 16806586
[TBL] [Abstract][Full Text] [Related]
14. Substantia nigra compacta neurons that innervate the reticular thalamic nucleus in the rat also project to striatum or globus pallidus: implications for abnormal motor behavior.
Anaya-Martinez V; Martinez-Marcos A; Martinez-Fong D; Aceves J; Erlij D
Neuroscience; 2006 Dec; 143(2):477-86. PubMed ID: 17008017
[TBL] [Abstract][Full Text] [Related]
15. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.
Dexter DT; Carayon A; Javoy-Agid F; Agid Y; Wells FR; Daniel SE; Lees AJ; Jenner P; Marsden CD
Brain; 1991 Aug; 114 ( Pt 4)():1953-75. PubMed ID: 1832073
[TBL] [Abstract][Full Text] [Related]
16. Iron deposition in Parkinson's disease by quantitative susceptibility mapping.
Chen Q; Chen Y; Zhang Y; Wang F; Yu H; Zhang C; Jiang Z; Luo W
BMC Neurosci; 2019 May; 20(1):23. PubMed ID: 31117957
[TBL] [Abstract][Full Text] [Related]
17. Nicotine-Induced Neuroprotection in Rotenone In Vivo and In Vitro Models of Parkinson's Disease: Evidences for the Involvement of the Labile Iron Pool Level as the Underlying Mechanism.
Mouhape C; Costa G; Ferreira M; Abin-Carriquiry JA; Dajas F; Prunell G
Neurotox Res; 2019 Jan; 35(1):71-82. PubMed ID: 30006684
[TBL] [Abstract][Full Text] [Related]
18. trkB messenger RNA expression in normal human brain and in the substantia nigra of parkinsonian patients: an in situ hybridization study.
Benisty S; Boissiere F; Faucheux B; Agid Y; Hirsch EC
Neuroscience; 1998 Oct; 86(3):813-26. PubMed ID: 9692719
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of thioredoxin reductase 1 expression in the substantia nigra pars compacta of Parkinson's disease mice.
Liu Z; Jing Y; Yin J; Mu J; Yao T; Gao L
Neural Regen Res; 2013 Dec; 8(35):3275-83. PubMed ID: 25206649
[TBL] [Abstract][Full Text] [Related]
20. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
